Pharmaceuticals Saudi Arabia

Saudi Arabia Atopic Dermatitis Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Saudi Arabia Atopic Dermatitis Drugs Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Drug Class, By Route of Administration, By Distribution Channel, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Saudi Arabia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $217.1 Mn Placeholder estimate
Estimate 2025 $246.8 Mn 1.7% of the global market
Projected 2034 $783.7 Mn 217.6% Adds $536.9 Mn over 9 forecast years
CAGR 2025–2034 13.7% Faster than 68% of 180 Pharmaceuticals markets here
Key players 11 +6
  • Saudi Arabia is 1.75% of the global market.
  • In Middle East, the largest is Saudi Arabia (this report) at $246.8 Mn.
  • Fastest growing: Saudi Arabia (this report) at 13.7% a year.
  • Saudi Arabia ranks 1st of 2 by size in Middle East.

Market size projection

Saudi Arabia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$536.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Atopic Dermatitis Drugs Market market size by year, Saudi Arabia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $217.1 Mn — —
2025 (base) $246.8 Mn +$29.7 Mn —
2026 (forecast) $280.6 Mn +$33.8 Mn +13.7%
2027 (forecast) $319.0 Mn +$38.4 Mn +29.3%
2028 (forecast) $362.8 Mn +$43.7 Mn +47%
2029 (forecast) $412.4 Mn +$49.7 Mn +67.1%
2030 (forecast) $469.0 Mn +$56.5 Mn +90%
2031 (forecast) $533.2 Mn +$64.2 Mn +116.1%
2032 (forecast) $606.2 Mn +$73.0 Mn +145.7%
2033 (forecast) $689.3 Mn +$83.1 Mn +179.3%
2034 (forecast) $783.7 Mn +$94.4 Mn +217.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Saudi Arabia Atopic Dermatitis Drugs Market Analysis at a glance
Market size, 2025$246.8 Mn placeholder estimate
Forecast, 2034$783.7 Mn placeholder estimate
Growth (CAGR), 2025–203413.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route of administration and distribution channel (see all)
Key playersSanofi, Pfizer Inc., AbbVie Inc., LEO Pharma A/S, Eli Lilly and Company and 6 more (see all)
Regulator in Saudi ArabiaSFDASource: Saudi Food and Drug Authority. Checked 14 Nov 2026.
Active clinical trials5 in Saudi ArabiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Saudi Arabia. Retrieved 9 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Saudi Arabia Atopic Dermatitis Drugs Market Executive Summary

Atopic dermatitis, also known as eczema, is a chronic skin condition which involves inflammation, redness and itching. While its typical onset is in childhood, RA can develop at any age and is not transmissible from one person to another. They manifest as severe itching, skin redness, inflammation, and dermatitis with eruptive phases and quiescent periods. The exact reason is still unknown, but genetic and heredity, immune, and environment could play a role. It is treatable and while it tends to be worse in childhood, it tends to reduce in adulthood and can even cause some problems.
Globally, 2.6% of the population, or 204 million people, are affected by atopic dermatitis (AD). This includes approximately 101 million adults and 103 million children. Additionally, findings indicate that females are more commonly affected by AD than males. Interventions consist of the topical corticosteroids of triamcinolone (Kenalog, Aristocort A and others) and systemic immunosuppressive agents, which include cyclosporine and methotrexate. This sector is emerging due to the improvements in the treatments and awareness of the disease. There are more recent biologics such as Dupixent, and the pool of nonsteroidal topical agents is seen to grow with the inclusion of roflumilast. Interests remain high or are rising in innovative therapies and treatment approaches with increased attention to natural therapies and telemedicine for better disease management.

Bar chart: Saudi Arabia Atopic Dermatitis Drugs market size, 2024–2034, placeholder estimates. $217.1 Mn in 2024, $246.8 Mn in 2025 and $783.7 Mn in 2034, 13.7% CAGR.
Saudi Arabia Atopic Dermatitis Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Saudi Arabia Atopic Dermatitis Drugs Market Dynamics

Market Growth Drivers

Atopic dermatitis is becoming more common in children and young adults, and this has led to the need for improvement in treatment options. Lifestyle changes, environmental factors, and heredity are some of the causes that could lead to this incidence. Newer agents including RINVOQ and Dupixent are more effective and safer for moderate to severe rheumatoid arthritis. Public awareness campaigns, like the World Atopic Eczema Day, and educational interventions are improving diagnosis and management. It is projected that the market will expand with novel biologics and small molecules, rising healthcare expenditures, and enhanced treatment availability, particularly in the developing world. Progress in technology is driving access of new treatments. The Asia Pacific region is expected to show the highest market growth based on factors such as improvement in health care access, increase in disposable income, and increase in health awareness.

Opportunity

The atopic dermatitis market has promising future prospects due to the emergence of new therapies. New nonsteroidal topical therapies like roflumilast and tapinarof and new biologics like lebrikizumab are also expected to expand patient choices, given approval. Awareness about atopic dermatitis and its psychological effects will enhance its diagnosis and treatment. Greater patient awareness and compliance with prescribed treatment plans will continue to expand the market. Opportunities include increased investment in biologics and new complex treatments and the adoption of telehealth and digital health solutions. There is also an increasing demand for natural and organic solutions. In conclusion, as the awareness and the need for management solutions rises, the market has the potential of growing significantly.

Market Restraints

High treatment costs for atopic dermatitis significantly limit patient access, discouraging therapy initiation and continuation due to financial burden. Regional differences in access to dermatological specialists further exacerbate this issue, with patients in areas with fewer specialists facing greater challenges. Complex treatment regimens and high costs often lead to poor adherence. As alternative treatments like herbal remedies gain popularity, traditional therapy providers may face decreased demand. Lack of awareness and inadequate diagnostic methods contribute to under-treatment and an increased disease burden.

Competitive Landscape for Atopic Dermatitis Drugs Market in Saudi Arabia

Key Players

Recent Developments:

February 2024, The U.S. Food and Drug Administration (FDA) and the European Medicines Agency have accepted filing submissions for nemolizumab to treat prurigo nodularis and atopic dermatitis. Additionally, the FDA has granted nemolizumab Priority Review status for prurigo nodularis.

January 2024, Glenmark, Pfizer launch Abrocitinib in India for Atopic Dermatitis

January 2024, Vtama Is Getting Ready to Elbow Its Way into the Crowded Field of Atopic Dermatitis Medications

Mergers and Acquisitions

June 2024, Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

2020, BMS's acquisition of MyoKardia was intended to enhance its cardiovascular portfolio, but it also signifies a broader strategy to diversify its therapeutic range, including dermatology products.

2020, AbbVie's acquisition of Allergan has notably strengthened its dermatology position by incorporating Allergan's skin care products and treatments, which complement AbbVie's existing atopic dermatitis offerings.

Healthcare Policies and Regulatory Landscape for Atopic Dermatitis Drugs Market in Saudi Arabia

Atopic Dermatitis Drugs in Saudi Arabia: rules, payment and research

The Saudi Food and Drug Authority (SFDA) registers medicines before sale.⁠[1] Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI).⁠[2] ClinicalTrials.gov lists 5 studies on Atopic Dermatitis Drugs that are recruiting, active or about to start in Saudi Arabia.⁠[3]

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Council of Health Insurance. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Saudi Arabia. Retrieved 9 Nov 2026.

Policy changes and Reimbursement scenario

Patients and clinicians are aware that regulatory agencies closely monitor the effectiveness and safety of atopic dermatitis therapies that can take time before new therapeutic options come into the market. However, in the case of severe atopic dermatitis, biologics are gradually receiving approvals from drug authorities, and research-based companies are enabling access to these state-of-the-art treatments. Due to drug escalation, the healthcare laws of many countries are being imposed to allow equitable insurance cover for dermatological expensive biologics. This is due to the fact that insurers are more concerned with the outcomes of the treatments rather than costs associated with such treatments and therefore reimbursement for such treatments is enhancing. Furthermore, patient assistance programs in pharmaceutical markets have also emerged to assist with out-of-pocket expenses however reimbursement is also different from country to country.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Atopic Dermatitis Drugs right now, from free public sources.

Clinical trials

5 active trials in Saudi Arabia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Sanofi 16 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Pfizer Inc. 14 active trials on ClinicalTrials.gov (opens in a new tab)
  3. AbbVie Inc. 9 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Keymed Biosciences Co.Ltd 5 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Almirall 4 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Atopic Dermatitis Drugs in context

Saudi Arabia compared

  • Health spending per person: 1,825 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 9 countries we cover in Middle East.[1]
  • Doctors: 3.41 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). Highest of the 9 countries we cover in Middle East.[2]
  • People aged 65 and over: 3.1% of people (2025). World: 10.4% of people (2025). 6th highest of the 9 countries we cover in Middle East.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Atopic Dermatitis Drugs market in Saudi Arabia?
Placeholder estimate: about $246.8 Mn in 2025, rising to about $783.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Atopic Dermatitis Drugs market in Saudi Arabia growing?
Placeholder estimate: about 13.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Atopic Dermatitis Drugs market report cover?
The report splits the market by drug class (Biologics, Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors and more), route of administration (Topical, Injectable, Oral) and distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Dermatology Clinics).
Who are the key players in the Atopic Dermatitis Drugs market?
Key players include Sanofi, Pfizer Inc., AbbVie Inc., LEO Pharma A/S, Eli Lilly and Company and Teva Pharmaceutical, among 11 companies the report profiles.
What is driving the Atopic Dermatitis Drugs market?
Atopic dermatitis is becoming more common in children and young adults, and this has led to the need for improvement in treatment options. Lifestyle changes, environmental factors, and heredity are some of the causes that could lead to this incidence.
Who regulates Atopic Dermatitis Drugs in Saudi Arabia?
The Saudi Food and Drug Authority (SFDA) registers medicines before sale. Source: Saudi Food and Drug Authority. Checked 14 Nov 2026.
How is healthcare paid for in Saudi Arabia?
Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI). Source: Council of Health Insurance. Checked 14 Nov 2026.
How many clinical trials on Atopic Dermatitis Drugs are running in Saudi Arabia?
5 studies are recruiting, active or about to start in Saudi Arabia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Saudi Arabia. Retrieved 9 Nov 2026.
How much research is published on Atopic Dermatitis Drugs?
PubMed lists 15,446 papers on Atopic Dermatitis Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 9 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Saudi Arabia

See all

Related on skin and hair and allergies

See the topic